FDA approves higher dose of Ozempic. The FDAhas approveda 2 mg dose of Ozempic (semaglutide) injection, a once-weekly glucagon-like peptide-1 (GLP-1) analog to improve blood sugar in adults with type 2 diabetes. Developed by Novo Nordisk, Ozempic is now available in three doses (0.5 mg...
FLOW studied the effect of semaglutide (1 mg) vs placebo on the progression of renal impairment in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). Why was it stopped? For efficacy, that is why. FLOW enrolled slightly more than 3500 patients in 28 countries. FLOW had...
JAMA Network Openhas published adrug safety study on the GLP-1 agonist semaglutidethat is making the rounds in the media. I have read the study and have one clear thing to say: pharmacovigilance is complicated. The topline results found a signal (an association) of semaglutide use and suicid...
There is limited information on the benefits of different exercise regimens on the regulation of CTRP12 in reducing inflammation in people with obesity. The benefits of effective and safe pharmacological agents such as the semaglutide for the management of obesity are in large part due to reducing ...
In the presentation titled “Single-Dose GLP-1-Based Pancreatic Gene Therapy Maintains Weight Loss After Semaglutide Withdrawal and Reduces Hepatic Triglycerides in a Murine Model of Obesity,” data showed that Rejuva reduced liver we...
Introduction: Once-weekly semaglutide is a novel glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes (T2D) that has been associated with greater reductions in glycated hemoglobin (HbA1c) and body weight versus GLP-1 receptor agonists dulaglutide, exenatide extended-release...
Top 5 Most-Read Heart Failure Articles of 2024 Hayden E. Klein Some of the top heart failure research looked at statins and semaglutide for heart failure with preserved ejection fraction, diabetes-related heart failure risks, and the protective cardiovascular effects of COVID-19 vaccination. Februar...
BMS-512148, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, JNJ-28431754, luseogliflozin, LX4211, remogliflozin, TA-7284, and tofogliflozin) and GLP-1 receptor agonists (albenatide, albiglutide, dulaglutide, efpeglenatide, exenatide, liraglutide, lixisenatide, and semaglutide)....
diabetes mellitus, type 2glucagon-like peptide-1 agonistssemaglutideRetrospective database studies have shown that switching between some GLP-1RAs may be associated with additional benefits on glycemic control and body weight (BW).This prospective post hoc analysis of pooled data from the SURE real-...
As background for the HFpEF question, two small STEP HFpEF trials have shown that semaglutide induces weight loss and improves quality of life in patients with HFpEF and obesity and type 2 diabetes. These trials enrolled small numbers of patients who had low numbers of HF events, so no conclu...